Right now, Second Sight expects the deal to close by the end of the third quarter. Current EYES stock holders will own roughly 23% of the combined company. As part of this, it will issue 134 million shares. Source: Shutterstock So what do you need to know? To start, Second Sight Medical is acquiring Nano Precision through an all-stock deal. Second Sight Medical (NASDAQ:EYES) stock is up 15% this morning after announcing a merger with Nano Precision. Bloomberg US is available in an estimated 73 million homes across the United States.ĮYES Stock Pops on Biotech Merger Plans. Today's Range N/A 50-Day Range 4.11 13.05 52-Week Range N/A Volume 36,800 shs Average Volume 132,982 shs Market Capitalization 54. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Second Sight Medical Products - EYES Options Chain & Prices Notice: This company has been marked as potentially delisted and may not be actively trading. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. LOS ANGELES, April 14, 2022-Second Sight Medical Products, Inc. Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. #Eyes stock trial#(NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health ("NIH") of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the "Orion Trial"), grant 5UH3NS103442. LOS ANGELES, July 18, 2022-Second Sight Medical Products, Inc. Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. LOS ANGELES, July 29, 2022-Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. William White on InvestorPlace | August 19, 2022 We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them! Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday Below are the latest news stories about SECOND SIGHT MEDICAL PRODUCTS INC that investors may wish to consider to help them evaluate EYES as an investment opportunity. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. #Eyes stock how to#Read More: Penny Stocks - How to Profit Without Getting Scammed If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that ’s writers disclose this fact and warn readers of the risks. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Prior to today’s move higher, the stock had declined 24% year to date and was down 65% over the last six months.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |